Sanofi MS drug suffers setback in key U.S. market

[riky]

Sanofi MS drug suffers setback in key U.S. market

<p><a href="http://news.yahoo.com/sanofi-says-u-regulators-reject-ms-treatment-lemtrada-061913292--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/hB1l6PTswFnuXa.14Vs79w--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-12-30T061913Z_1_CBRE9BT0HKM00_RTROPTP_2_SANOFI-RESULTS.JPG" width="130" height="86" alt="Chris Viehbacher, CEO of Sanofi, attends the company's 2012 annual results presentation in Paris" align="left" title="Chris Viehbacher, CEO of Sanofi, attends the company's 2012 annual results presentation in Paris" border="0" /></a>By James Regan and Natalie Huet PARIS (Reuters) - Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme. The U.S. Food &amp; Drug Administration (FDA) rejected Lemtrada for launch in the world's biggest drug market on the grounds that Genzyme had not shown its benefits outweighed its &quot;serious adverse effects&quot;, Sanofi said on Monday. The FDA also demanded Sanofi carry out further clinical trials using different designs and methods prior to approval, Sanofi said.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login